Back to Newsroom

Oncobiologics Announces ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial

CRANBURY, N.J., Oct. 5, 2015 /PRNewswire/ — Oncobiologics, Inc. (“Oncobiologics”) announced that its bevacizumab (Avastin®) biosimilar candidate, ONS-1045, met the primary and secondary endpoints in a Phase 1 clinical trial.

Click here to read more